Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial
Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial
Daoyu Zhang, Yunfang Chen, Min Seob Song, Zhiye Zhang et al.
Citations
5 citations
Journal
Molecular Cancer
Topics
Esophageal Cancer Research and Treatment
Field-Weighted Citation Impact (FWCI)
10.03
article
Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial
Daoyu Zhang, Yunfang Chen, Min Seob Song, Zhiye Zhang, Wenkang Wang, Taiying Lu, Biao Hu, Guozhong Jiang, Ling Shen, Xi Luo, Lisen Wang, Yue Zhou, Xiuli Yang, Bing‐Hua Jiang, Zhengzheng Shan, Feng Wang, Lulu Guan, Zuofu Peng, Dao Xin, Yu Qi, Xiaoying Wu, Mingying Ma, Tao Wu, Xiangrui Meng, Yihui Ma, Jin Xia, Weilong Wu, Yonggui Hong
article en
5 citations
Abstract
No abstract available for this paper.
Publication Tag
Molecular CancerVol. 24(1)
Institutions
Sinovac Biotech (CN), Zhumadian Central Hospital (CN), First Affiliated Hospital of Henan University of Science and Technology (CN), Nanyang Medical College (CN), Henan Cancer Hospital (CN), First Affiliated Hospital of Zhengzhou University (CN), Anyang Tumor Hospital (CN)